IL17A and psoriasis: Based on our current understanding of the immunopathogenesis of psoriasis, biologics have emerged that target TNF, IL-12/IL-23p40 subunit, IL-23p19 subunit, IL-17A, and the IL-17 receptor α chain (IL-17RA) [50,52,53].